Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $110,552 | $91,542 |
| Restricted cash | 7,868 | 7,565 |
| Trade accounts receivable, net | 775,731 | 613,732 |
| Inventories | 612,454 | 581,384 |
| Prepaid expenses and other current assets | 80,717 | 82,685 |
| Related party receivables | 484 | 955 |
| Total current assets | 1,587,806 | 1,377,863 |
| Property, plant and equipment, net | 424,908 | 447,574 |
| Goodwill | 597,436 | 598,629 |
| Intangible assets, net | 732,377 | 890,423 |
| Operating lease right-of-use assets | 31,388 | 30,329 |
| Operating lease right-of-use assets - related party | 10,964 | 12,954 |
| Financing lease right-of-use assets | 56,433 | 59,280 |
| Other assets | 60,133 | 55,517 |
| Total assets | $3,501,445 | $3,472,569 |
| Liabilities and Stockholders’ (Deficiency) Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $735,450 | $534,662 |
| Current portion of liabilities for legal matters | 31,755 | 76,988 |
| Revolving credit facility | 100,000 | 179,000 |
| Current portion of long-term debt, net | 224,213 | 34,125 |
| Current portion of operating lease liabilities | 9,435 | 9,207 |
| Current portion of operating lease liabilities - related party | 3,396 | 2,825 |
| Current portion of financing lease liabilities | 3,211 | 2,467 |
| Related party payables - short term | 22,311 | 7,321 |
| Total current liabilities | 1,129,771 | 846,595 |
| Long-term debt, net | 2,161,790 | 2,386,004 |
| Note payable - related party | — | 41,447 |
| Operating lease liabilities | 24,814 | 24,095 |
| Operating lease liabilities - related party | 9,391 | 12,787 |
| Financing lease liabilities | 56,889 | 58,566 |
| Related party payable - long term | 50,900 | 11,776 |
| Liabilities for legal matters - long term | 85,479 | 316 |
| Other long-term liabilities | 26,949 | 29,679 |
| Total long-term liabilities | 2,416,212 | 2,564,670 |
| Commitments and contingencies (Notes 5, 20 and 23) | ||
| Redeemable non-controlling interests | 64,974 | 41,293 |
| Stockholders’ (Deficiency) Equity: | ||
| Preferred stock, $0.01 par value, 2,000 shares authorized at December 31, 2024 and 2023; none issued at both December 31, 2024 and 2023 | — | — |
| Class A common stock, $0.01 par value, 900,000 shares authorized at both December 31, 2024 and 2023; 309,881 and 306,565 shares issued at December 31, 2024 and 2023, respectively | 3,099 | 3,066 |
| Class B common stock, $0.01 par value, 300,000 shares authorized at December 31, 2024 and 2023; none issued at December 31, 2024 and 2023 | — | — |
| Additional paid-in capital | 560,206 | 539,240 |
| Stockholders' accumulated deficit | (607,062) | (490,176) |
| Accumulated other comprehensive loss | (65,510) | (32,349) |
| Total Amneal Pharmaceuticals, Inc. stockholders' (deficiency) equity | (109,267) | 19,781 |
| Non-controlling interests | (245) | 230 |
| Total stockholders' (deficiency) equity | (109,512) | 20,011 |
| Total liabilities and stockholders' (deficiency) equity | $3,501,445 | $3,472,569 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.